Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback